As global markets experience mixed performance, with US small-cap indexes performing well, Hong Kong’s high-tech sector continues to attract investors’ strong growth potential despite broader market challenges. It is attracting attention. In this dynamic environment, identifying promising tech stocks requires a keen eye for innovation and adaptability to evolving economic conditions.
name
increase in revenue
revenue growth
growth assessment
Wasion Holdings
22.37%
25.47%
★★★★★☆
Medsai Healthcare Holdings
48.74%
48.78%
★★★★★☆
Inspur Digital Enterprise Technology
23.28%
38.77%
★★★★★☆
remegen
26.23%
52.03%
★★★★★☆
Innovent Biologics
22.11%
59.31%
★★★★★☆
Akiso
33.50%
53.12%
★★★★★
Cowell E Holdings
31.68%
35.44%
★★★★★
Biocytogen Pharmaceuticals (Beijing)
21.53%
109.17%
★★★★★☆
beijing air dock technology
37.47%
93.35%
★★★★★☆
Sichuan Cologne-Biotech Biopharmaceutical
24.70%
8.53%
★★★★★☆
Click here to see the complete list of 43 stocks in the SEHK High Growth Technology Stock and AI Stock Screener.
Let’s take a look at some of the main choices from the screener.
Simply Wall Street Growth Rating: ★★★★★☆
Overview: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company with a market capitalization of 43 billion yen, focused on the research, development, manufacturing, and commercialization of new drugs to address unmet medical needs in China and abroad. HK$30 million.
What it does: The company derives its revenue primarily from the pharmaceutical segment, which amounts to CAD 1.88 billion. We are engaged in the development and commercialization of innovative medicines that target unmet medical needs both domestically and internationally.
Sichuan Kelun-Biotech Biopharmaceutical has made significant progress in the field of biotechnology, particularly with its innovative drug sacituzumab tilmothecan (sac-TMT), which has shown solid clinical results. Recent presentations at major medical conferences have shown that compared to standard chemotherapy, the results include a 68% reduction in the risk of disease progression and significant improvements in median progression-free survival (PFS) rates in a variety of cancers. Promising results are highlighted. These developments are crucial as the company’s revenue has increased by 24.7% over the past year, underscoring its growth trajectory amid expanded research and development activity, which accounts for a significant portion of its budget. Sichuan Kelun-Biotech’s inclusion in the FTSE All-World Index highlights the company’s growing profile on a global scale and positions it well for future advances in high-growth biotechnology applications.
story continues
SEHK:6990 Breakdown of revenue and expenses as of October 2024
Simply Wall Street Growth Rating: ★★★★☆
Overview: Lenovo Group Limited is an investment holding company that develops, manufactures and sells technology products and services with a market capitalization of HK$143.15 billion.
Business Operations: Lenovo Group primarily generates revenue through the Intelligent Devices Group (IDG), which accounts for $45.76 billion, followed by the Infrastructure Solutions Group (ISG), which accounts for $10.17 billion, and the Solutions and Services Group ( SSG) was $7.64 billion. The company focuses on diverse technology products and services across these segments.
Lenovo Group is actively leveraging its research and development capabilities, devoting a significant portion of its revenue to these efforts, which has increased significantly to 18.7% over the past year. This investment will drive innovations such as Alzheimer’s Intelligence Avatar and a strategic partnership with NVIDIA, strengthening Lenovo’s product offering in AI and hybrid cloud solutions. These efforts not only reflect Lenovo’s commitment to integrating AI into various technology areas, but also position Lenovo uniquely within Hong Kong’s high-growth technology environment despite the competitive market. I am. A recent partnership with Red Hat to optimize AI applications on servers further underscores Lenovo’s commitment to becoming an essential player in enterprise-level AI solutions, helping to position the company for the future in an increasingly digital economy. Promising growth prospects.
SEHK:992 Breakdown of revenue and expenses as of October 2024
Simply Wall Street Growth Rating: ★★★★★★
Overview: Akeso, Inc. is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of antibody therapeutics with a market capitalization of approximately HK$58.01 billion.
What it does: Akeso primarily generates revenues of C$1.87 billion from research, development, production and sales of biopharmaceuticals. The company is involved in the development of antibody drugs and operates in the biopharmaceutical field.
Akeso’s recent strategic moves highlight the company’s potential in Hong Kong’s technology-driven biopharmaceutical sector. The company reports a solid revenue growth forecast of 33.5% annually, above the domestic market average of 7.4%. This growth is fueled by Akeso’s significant R&D investments, which align with industry trends towards innovative drug development in oncology and other areas. Notably, revenue is expected to grow 53.1% annually, reflecting both the pipeline’s high commercialization potential and effective expansion strategy. The company’s focus on dual immune checkpoint inhibitors, such as cadnilimab, highlights its pioneering approach in cancer treatment, setting new standards in therapeutic efficacy and patient care across multiple indications. There is a possibility.
SEHK:9926 Breakdown of revenue and expenses as of October 2024
This article by Simply Wall St is general in nature. We provide commentary using only unbiased methodologies, based on historical data and analyst forecasts, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.
Companies covered in this article include SEHK:6990 SEHK:992 and SEHK:9926.
Do you have feedback on this article? Interested in its content? Please contact us directly. Alternatively, email us at editorial-team@simplywallst.com.
